Co-Diagnostics Inc (CODX) FinancialsCODXFinancialCo-Diagnostics Inc

Evaluating the bottom line, Co-Diagnostics Inc maintains a gross margin of -48.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3732.47%, while the net margin is -3782.43%. These profitability ratios, combined with a Return on Equity (ROE) of -178.00%, provide a clear picture of how effectively CODX converts its operational activities into shareholder value.

In the context of the broader market, CODX competes directly with industry leaders such as EVGN and XCUR. With a market capitalization of $8.80M, it holds a significant position in the sector. When comparing efficiency, CODX's gross margin of -48.76% stands against EVGN's 40.63% and XCUR's N/A. Such benchmarking helps identify whether Co-Diagnostics Inc is trading at a premium or discount relative to its financial performance.

Co-Diagnostics has shown a consistent pattern of financial losses, with a net income loss of $6.3 million in Q2 2026 and a gross margin of -48.76%. This trend raises concerns about the company's ability to achieve profitability in the near future.